Ultifend ND IBD

RSS
Authorised

This medicine is authorised for use in the European Union

Newcastle disease / infectious bursal disease / Marek's disease vaccine (live recombinant)
Medicine Veterinary Authorised
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Ultifend ND IBD : EPAR - Medicine overview

Reference Number: EMA/145332/2021

English (EN) (81.94 KB - PDF)

First published: Last updated:
View

български (BG) (93.36 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

español (ES) (81.97 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

čeština (CS) (93.99 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

dansk (DA) (83.34 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Deutsch (DE) (82.76 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

eesti keel (ET) (82.18 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

ελληνικά (EL) (93.76 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

français (FR) (82.44 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

hrvatski (HR) (92.27 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

íslenska (IS) (83.29 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Gaeilge (GA) (83.57 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

italiano (IT) (82.29 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

latviešu valoda (LV) (94.29 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

lietuvių kalba (LT) (94.03 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

magyar (HU) (94.15 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Malti (MT) (95.95 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Nederlands (NL) (82.05 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

norsk (NO) (82 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

polski (PL) (95.62 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

português (PT) (83.01 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

română (RO) (94.17 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

slovenčina (SK) (94.08 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

slovenščina (SL) (82.27 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Suomi (FI) (81.54 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

svenska (SV) (82.05 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Product information

Ultifend ND IBD : EPAR - Product information

English (EN) (81.49 KB - PDF)

First published: Last updated:
View

български (BG) (91.78 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

español (ES) (81.51 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

čeština (CS) (92.48 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

dansk (DA) (82.05 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Deutsch (DE) (81.72 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

eesti keel (ET) (81.22 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

ελληνικά (EL) (91.79 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

français (FR) (81.63 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

hrvatski (HR) (91.56 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

íslenska (IS) (81.52 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Gaeilge (GA) (81.36 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

italiano (IT) (81.76 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

latviešu valoda (LV) (92.14 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

lietuvių kalba (LT) (92.19 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

magyar (HU) (92.76 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Malti (MT) (93.86 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Nederlands (NL) (81.15 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

norsk (NO) (81.52 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

polski (PL) (93.22 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

português (PT) (82.53 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

română (RO) (91.73 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

slovenčina (SK) (81.75 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

slovenščina (SL) (81.76 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Suomi (FI) (81.11 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

svenska (SV) (81.47 KB - PDF)

First published: 21/09/2021 Last updated: 15/10/2025
View

Product details

Name of medicine
Ultifend ND IBD
Active substance
turkey herpes virus, strain rHVT/ND/IBD, expressing the fusion protein of Newcastle disease virus and the VP2 protein of infectious bursal disease virus, live recombinant
International non-proprietary name (INN) or common name
  • Newcastle disease
  • infectious bursal disease
  • Marek's disease vaccine (live recombinant)

Pharmacotherapeutic group

Immunologicals for aves

Authorisation details

EMA product number
EMEA/V/C/005347

Assessment history

Ultifend ND IBD : EPAR - Public assessment report

Adopted Reference Number: EMA/160757/2021

English (EN) (81.49 KB - PDF)

First published: Last updated:
View

CVMP summary of positive opinion for Ultifend ND IBD

Adopted Reference Number: EMA/CVMP/74964/2021

English (EN) (143.31 KB - PDF)

First published:
View
This page was last updated on

Share this page

Back to top